KALA BIO Future Growth

Future criteria checks 0/6

KALA BIO's earnings are forecast to decline at 11.3% per annum. EPS is expected to grow by 46.9% per annum.

Key information

-11.3%

Earnings growth rate

46.9%

EPS growth rate

Biotechs earnings growth	27.6%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	Low
Last updated	15 Nov 2024

Recent future growth updates

Recent updates

The Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Analysts Have Been Trimming Their Sales Forecasts

Aug 10

Is Kala Pharmaceuticals (NASDAQ:KALA) Using Debt Sensibly?

Jul 07

Earnings and Revenue Growth Forecasts

NasdaqCM:KALA - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	N/A	-45	N/A	N/A	2
12/31/2024	N/A	-41	N/A	N/A	2
9/30/2024	N/A	-39	-33	-32	N/A
6/30/2024	N/A	-39	-31	-31	N/A
3/31/2024	N/A	-40	-30	-29	N/A
12/31/2023	N/A	-42	-29	-28	N/A
9/30/2023	N/A	-46	-35	-34	N/A
6/30/2023	0	-9	-47	-47	N/A
3/31/2023	3	-26	-65	-65	N/A
12/31/2022	4	-45	-79	-79	N/A
9/30/2022	6	-80	-93	-93	N/A
6/30/2022	8	-137	-104	-103	N/A
3/31/2022	9	-145	-100	-100	N/A
12/31/2021	11	-143	-109	-108	N/A
9/30/2021	12	-126	-108	-106	N/A
6/30/2021	11	-126	-107	-106	N/A
3/31/2021	9	-113	-105	-103	N/A
12/31/2020	6	-104	-93	-91	N/A
9/30/2020	5	-95	-85	-83	N/A
6/30/2020	5	-90	-82	-80	N/A
3/31/2020	6	-91	-83	-81	N/A
12/31/2019	6	-94	-94	-93	N/A
9/30/2019	5	-98	-93	-90	N/A
6/30/2019	3	-90	-86	-84	N/A
3/31/2019	1	-81	-74	-73	N/A
12/31/2018	N/A	-67	-56	-54	N/A
9/30/2018	N/A	-53	-46	-45	N/A
6/30/2018	N/A	-47	N/A	-38	N/A
3/31/2018	N/A	-44	N/A	-37	N/A
12/31/2017	N/A	-42	N/A	-34	N/A
9/30/2017	N/A	-39	N/A	-35	N/A
6/30/2017	N/A	-39	N/A	-34	N/A
3/31/2017	N/A	-38	N/A	-32	N/A
12/31/2016	N/A	-33	N/A	-27	N/A
9/30/2016	N/A	-30	N/A	-24	N/A
6/30/2016	N/A	-25	N/A	-19	N/A
3/31/2016	0	-18	N/A	-16	N/A
12/31/2015	0	-17	N/A	-15	N/A
9/30/2015	0	-17	N/A	-16	N/A
6/30/2015	0	-17	N/A	-17	N/A
3/31/2015	0	-18	N/A	-16	N/A
12/31/2014	0	-19	N/A	-15	N/A
12/31/2013	0	-11	N/A	-11	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: KALA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: KALA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: KALA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if KALA's revenue is forecast to grow faster than the US market.

High Growth Revenue: KALA is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if KALA's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/27 13:05
End of Day Share Price	2024/12/27 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

KALA BIO, Inc. is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Tazeen Ahmad	BofA Global Research
Yi Chen	H.C. Wainwright & Co.
Raghuram Selvaraju	H.C. Wainwright & Co.

KALA BIO Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased by 15% to US$16.50

Price target decreased by 13% to US$26.00

Price target decreased by 9.7% to US$31.00

Consensus forecasts updated

Price target decreased to US$42.00

Price target decreased to US$90.67

Recent updates

New major risk - Share price stability

Price target decreased by 15% to US$16.50

New major risk - Shareholder dilution

KALA BIO, Inc. announced that it has received $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

KALA BIO, Inc. announced that it expects to receive $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

KALA BIO, Inc. announced that it expects to receive $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

Chairman & CEO notifies of intention to sell stock

KALA BIO, Inc., Annual General Meeting, Jun 11, 2024

KALA BIO, Inc. announced that it expects to receive $8.599799 million in funding from Baker Bros. Advisors LP

KALA BIO, Inc. announced that it expects to receive $1.999824 million in funding

New minor risk - Share price stability

Price target decreased by 13% to US$26.00

Price target decreased by 9.7% to US$31.00

New major risk - Revenue size

First half 2023 earnings released: US$11.35 loss per share (vs US$41.26 loss in 1H 2022)

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 22, 2023

First quarter 2023 earnings released: US$6.99 loss per share (vs US$22.37 loss in 1Q 2022)

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Kala Pharmaceuticals, Inc. announced that it has received $30.999475 million in funding from Baker Bros. Advisors LP

Kala Pharmaceuticals, Inc. Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Kala Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

Consensus forecasts updated

Kala Pharmaceuticals, Inc. announced that it expects to receive $30.999475 million in funding from Baker Bros. Advisors LP

Price target decreased to US$42.00

Price target decreased to US$90.67

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Kala Pharmaceuticals, Inc. Announces Appointment of Marjan Farid to Its Board of Directors

Kala Pharmaceuticals to execute reverse stock split

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Kala Pharmaceuticals Q2 2022 Earnings Preview

Kala Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Kala Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Alcon Pharmaceuticals Ltd and Alcon Vision, LLC completed the acquisition of EYSUVIS® and certain assets of Kala Pharmaceuticals, Inc. (NasdaqGS:KALA).

Kala Pharmaceuticals Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Alcon Inc. (SWX:ALC) entered into a agreement to acquire EYSUVIS® and certain assets of Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $385 million.

Consensus revenue estimates fall by 27%

Alcon Inc. (SWX:ALC) acquired EYSUVIS® from Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $60 million.

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Kala Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 16, 2022

Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2022

Price target decreased to US$4.55

Insufficient new directors

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Third quarter 2021 earnings released: US$0.43 loss per share (vs US$0.50 loss in 3Q 2020)

Staying Patient With Kala Pharmaceuticals

Consensus revenue estimates fall to US$19.9m

The Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Analysts Have Been Trimming Their Sales Forecasts

Price target decreased to US$16.50

Second quarter 2021 earnings released: US$0.56 loss per share (vs US$0.42 loss in 2Q 2020)

No longer forecast to breakeven

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Is Kala Pharmaceuticals (NASDAQ:KALA) Using Debt Sensibly?

Consensus forecasts updated

First quarter 2021 earnings released: US$0.49 loss per share (vs US$0.54 loss in 1Q 2020)

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics